ONVO - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone and welcome to the Organovo Holdings, Inc. Fourth Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that this event is being recorded. like Investor the Relations. now Steve over would of Kunszabo I to conference turn to And Please ahead. go

Steve Kunszabo

Good afternoon, XXXX and to welcome thanks for joining to fiscal us. our fourth quarter earnings you call. I'd like

CFO, year Scientific discussion the call call full will Presnell. fourth followed Paul are Crouch; General Joining me of President Q&A. fiscal Craig our of quarter this our Chief on Kussman; and Today's a the and by CEO, XXXX begin afternoon results, Taylor with our Officer Gallant Sharon Manager, Samsara,

I things caution of Act statements Private call may Before turn I'd the over like Reform forward-looking all this XXXX. to to contain within Taylor, of Litigation our the meaning participants that Securities afternoon

about are to expectations, with forward-looking the to our prospects. and Such Such Forward-looking are upon expectations, cause based filings and actual future results Securities differ discussed in historical are statements that statements are plans, statements Commission. statements current which Exchange our could the subject not risks and fully from beliefs our risks, are and more statements. include facts, forward-looking and

be statements should in future, as while change. considered do to of our we or may disclaim if and expectations light update risks. Any of today views point forward-looking views statements today, remarks Our we to any obligation elect only at such some represent forward-looking our in specifically the so, even

non-GAAP financial measures. today's me definition principles. not a call, be accounting that, earnings non-GAAP non-GAAP are During measures. referring to measures things also these over financial for we'll These in certain of release the to Taylor. turn generally let accordance to prepared refer Please accepted With with financial

Taylor Crouch

everyone. afternoon, good and Steve Thanks,

a up, transformative one we year fiscal sustainable reflecting how wrapped to how human just define and way busy all of We're different bring and remarkable to to for a tissues ourselves, the ago. organization me our and the us. were future ability on growing technology which is aim by year the evolved We've the we stakeholders. much functionality. a value of Let in for we and customers than we we bioprint pioneering period patients, start Organovo create XD ultimately, our platform company, value biotech was with

a platform diseases adult and our in to And to providing the term. harnessing pediatric a of mission potentially platform. are today, successfully treat our are this access range by medium of We clients liver growing portion our technology therapeutic funding we

Our transplantation. options primary there diseases and goal life-threatening to a organ rare to which is group other therapeutics for than novel treatment current few our of develop own treat are

NovoTissues, healthy offering range R&D, terms product address potentially and manufacturing, tissue in the broad can Our process. liver a of important development indications, de-risking of target synergies

our market. Our this advance failure, peak represents our capture target in disease customers multiple generate facilitate for and other programs. the metabolism, diseases and objective unmet NovoTissues as alone should disease that revenue billion liver areas. to same or induce able we typically common platform, in into for is medical research order work be term to may development cycle modeling discovery our to by their unmet FDA serious approaching of way a liver bodies transplant, the the need commencing revenues represents AXAT. liver regulatory value with liver to we simultaneously total disease. deficiencies, single development have the deficiency this areas peak attractive in indication $X near mutation platform critical research these liver Alpha-X-antitrypsin FDA Because and to capabilities provides programs Using in to with working acute-on-chronic today, our exceeding inborn And We just areas, are IND-track achievable and that incentives believe other billion. is our path each indication such create allowing own need, opportunity access the along note, $X through of to a to urea opportunity streamline we in in closely the end the various to Adding be

specialized to cells ability foundational mimic steatohepatitis, tissues fatty human conditions characterize robust and and to NAFLD; build that to opportunity custom led has the of models disease, functional liver human Our NASH. disease non-alcoholic develop us non-alcoholic

continue might to range development the internal programs, number rapidly of research their explore our clients programs. a conditions growing work platform with Given for of to to add NASH value we adopter early which will tissue

functionality of the disease degree benefit high would a awaiting limited. to showing This features, a Now, translatable our XXXX XXXX, and first in severely to several fiscal significant liver significant if days. way patches big where our supply humans, I'd track disease with we a indication, taken build program. timeframe, into like programs. reduction through is already for our transplant, goals mice, fiscal outline patients therapeutics AXAT, XXX implanted and life-saving We've out IND offer to to in steps beginning our In therapeutics our perhaps full all

We treatment disease. our with that also status reached milestone for NovoTissues of granting for first the our program, orphan FDA AXAT regulatory the

will look to IND-enabling steps I XXXX. for the begin the over next As studies out this fiscal program complete XX months, we in necessary

we’ll finalize path scientific In for first successful a closely and to addition, to the with hope validation this for confirmatory we the and key work animal need to indication. meeting follow FDA pre-IND advisors studies

receive also a patient early model by as areas age. causes caused enzyme liver animal the known of new an X frequently type disease therapeutic a FAH in inborn second of indication within the This and new requires deficiency damage the metabolism. tyrosinemia studies severe liver We second at the began of to category commonly

industry good we of have survival established our As for improved this release, a few our ago preliminary weeks as functionality in animal of in showing and condition. proof-of-principle an presented conference recent models as tissues read press data rates well may evidence at human you retention

our indication on submissions IND studied designation or look similar tissue this we FDA disease same current XXXX, constructs we’ll therapeutic in orphan the year pursue rest of this like XXXX. work validate using for to with being our ahead As the as for with tissue the fiscal liver Much AXAT. fiscal are track with first of to two area ending the we’ll program, goal programs in

You can important and to revolutionary the programs updates conferences major of throughout therapeutics present industry year. expect scientific these at us

block have quickly development total in cell uptake immediate than mentioned, advancing are The while platform access during our for through cornerstone broad for financial As our primary of programs, our platform of making more to cells, and revenue clients’ has fiscal our generated tripled tissue A capitalizes continue growth. cells is our products in supporting become ability capabilities. for our This and our platform contribution animal revenues our wholly we to I validation new subsidiary, collaborators, by XXXX, pipeline owned human disease liver scientific we're technology year. by in-vivo this strides also clients. and human models on potential generate of our provided to research procure our of while building our this and therapeutics program. to robust demand Samsara in quality and Samsara, stream partners, pathway that its create based a revenue provides therapeutic tissues support business of a the characterize which also high expect to the our providing we're also ideas has access studies, to of and range great value key

of world's ingredient announced suppliers to and biopharma Solutions, multi-year markets agreement largest Bioscience recently further with contract date represents Our the leading trajectory. to and one healthy a Lonza growth Samsara’s specialty supports

full between of disease relations trends patient-on-a-plate we the the Samsara and results Importantly, testing key can capability of time Samsara’s and capabilities. the platform in a to provide cost conducting we clients clinical our a believe work translatable, close spanning will larger of predictive indicator trials. with our create a fraction namely human customers ability market which often and potential of lead real Because outcomes, human to have serves relationship be as its to partnering of

As communicate to a Liver candidate advances research NASH Summit, our generating already Similar considerable NASH the recognition. clinic. in to been and novel platform of lead to our commitment will turn spectrum aspects solutions advantage teasing from the out in drug continue R&D in believe progress comprehensive to as participate to Liver profiling AASLD, result, our The will therapeutics targeting we Congress; venues such us where our have across Meeting; drugs we the International provide The competitive on to program, to clients EASL,

and Finally, as up continue with In will closing, in platform milestones we is tissue a our platform our build to tissue IP patents fiscal exciting and with program our sight year the portfolio, applications. functionality advance global for clinic, shaping the operations. to be both includes therapeutics of number XXX XXXX eyes over important we our which today out on of pending an

liver by a bolstered ability We team and have with transform of outstanding Organovo, the to partners at an group collaborators health.

knowledge to continue XD bio-printing opportunities new generate based and body on As tissues. horizons our of pipeline around we’ll such, functional growing

As to it our always, financial ahead. for review. I in I'll updating to look you regularly more turn forward the over a progress complete that, With months Craig on

Craig Kussman

contribution our conclude quick good XX% we'll year-over-year total from for thoughts modeling and my total by and and cost business. sequentially. the our for were X% increase the the strategy, from decline, $X.X sheet $X driven XX% of few our fiscal operating selling, period million a grant general million, organizational fiscal goals revenue based one-time quarter, higher capital XX% fourth our lab comments by And revenue disease a a to start subsidiary finally, prioritization generated of thoughtful management higher decrease, brief recorded by at-the-market, a I'll by studies. and million driven restructuring R&D quarter with $XX profile. during down bigger then or to year-over-year review Samsara approximately fourth from fourth reflecting reported revenue on the $X.X costs. the quick XXXX fiscal ongoing $X.X sheet million, and between well key and lower and year focus everyone. announced year and and from on our on Taylor liquidity in the and to prior requirements, operating We ATM, also afternoon, be for CEO related costs primarily of projects. discussion The year fiscal next employee net our year-over-year into were We On future of improvement profile. today XXXX. a due fiscal fiscal expenses up of I'll stock cash million supported our XXXX and fourth and of expenses. forecast review in Thanks, a costs metrics we have significant commercial summarizing a quarter, resulting development will Research and liquidity of transition was period, financial our recap We capital full a largely continue from a the results non-cash prior the including lower quarter financing million cash and utilization payments. and opportunities. for balance XX% supply from utilization rate expenses expenses. funds we our Organovo net sufficient our a basis, employee requirements the our $X.X I'll our compensation to meet revenues of million liver administrative R&D which and and SG&A believe $XX balance we year in fiscal included programs

a total overall outlook business. parts revenue all with specific growth while XXXX, providing from we not our for our expect coming target, do for we contributions of are As fiscal

equivalents shares carry million had from At a of end facility, under fiscal ATM our $XX included we new the of in have of ATM. quarter, available for $XX.X issuance of plans. access we balance the million, approximately in $X.X proceeds to offerings. out balance Now, $XX cash funds million million of sheet. cash of stock our which common X.X development R&D and the our net million capital With to fourth

proposal facility lets wrapping continue to sheet up, long our market be way, capital, our treat with to in authorized increase shareholders the ATM ATM the balance to a value R&D it's own consider of to our encourage business. We strategy, In and to the annual to seeking clinic we runway of programs. in proposal. and us important pass, as same. this capital to moving cash tissue of while an two for the our favor and our forward facility plans. for cell dynamic extend order us In have as Related operational meaningful complimentary opportunistically into of we’ll meeting July. disciplined favor our is circumstances done in common our XXXX. this business, flexible be we’ll I’ll as measure, points As the voted our majority during providing must lead tool through stock stock at strengthen term in and our as that inflection value ongoing to permit, this dynamics while to platform key with move products successfully components We're financing for outstanding our the that The in we've clients a our to key an paths access common vote reflect use we also and process harmonious IND critical These do to solutions allows the based our access synergies. disease, are developing commercial, therapeutic on creating total

for call. Q&A plan afternoon’s to With productive opportunities, stewards while also the I'll We look things burn these successful of operator rate. of XXXX. that, our we to to fiscal forward execute this mindful Importantly, portion against turn cash the being back a and

Operator

our Reni James. with questioner Instructions] will be Benjamin [Operator Raymond first And today

Reni Benjamin

Is revenue this this I bit? You but what it's for seems terms a that stream it a will we’re kind disease seems model you total kind clarity from to enough to that's steady about shift kind what's easy at occurring in just there kind outlook? two the of but making a or revenue pretty and dynamic revenue start tougher be to about of to think like of happening? least the are of Craig, type to lack with, revenue of leading generating outlook of little of it year, sort off models thinking to talk it the be programs, what provided of guess can that positive, kind

Taylor Crouch

clearly is question. Hey, I Ren, your concern appreciate Taylor. this and Why and start, don’t thoughtful

is, And is on over revenue looked concluded the try back our of a predict our that we projects Samsara timing, you’ve able adopters to the best same uptake quite developed all and results, to the points. and revenue to revenue are theme next are rarely requiring immediate a cool while to stream research outshot commit to pursue is is of projects, to the predict we of which other are As a this adopters at early project for first what's but needs. streams okay, there specific on last to side, nice very design evaluated will a typically thing is customization step. the giving elements reason cool lead words, found see discussion growing significant for lengthy project. of and shareholders recurring a year-and-a-half providing the those of, inflection guidance, approach aimed that some their customizing modeling In unpredictable what our project which want we scientific and break that disservice we disease one have we the with the business some side, a next to and rapid we've we've things, Typically to functionality, and

think to really of way. we’ve our begun a so, in And completely different revenues

that new the business be and blocks build and pipeline a of first as validation those we're from way tissues destined ultimately First to value using, validation partners. we now of as value mechanisms a unlocked do for pipeline we’re valuable kinds for building that we key foremost, and to therapeutics functionality collaborations. our And believe tremendous XD-bioprinted generate these and of building tissues that downstream we the finally, our that and to exploration new funding have main opportunity view have and a ideas. mission, the they're actually, to functionality foremost, But the and

much goals therapeutic our to of P&L orientation bring to the a from moving marketplace. heavily we're midterm that So and just side the business tools to focusing away on products more fundamentally or

Reni Benjamin

team of expanding do be the X to diagnostic and beyond therapeutics sense. off to we or end with going this to more from. about want relation of that, could right a to And more Would be stick XXXX? I'm the of me the development. near to lot have little P&L closer transformation incorrectly, Is makes It of kind in indications you the and transformation sort we the Do you're platform we in Thanks, guys more just at thinking of or are kind team R&D two really guess disease moves be right I involves how love bit of indications seems kind Taylor. at about future X something this a so side this to -- of of you you the thinking be company. kind spring of the That and where let now, probably and NASH learn to something into I’d type That is that it? expertise, feel that different looking AXAT on for? the the guys typically a

Taylor Crouch

exactly spent chunks drug company the and first, from classic that add with be we is big I ultimately to Well, other of some that as very companies development clearly, look clearly in think raised, phases will phase, of typically the years, the I move will of studies. move that we But to targeting that hair clinic. will from you my in career coming as to toward. development, my the loss that discovery point areas clinical expertise fact results a in important toward the over in-human INDs point first moving

and a have developed has a I cutting also But clinical is unique to as point-of-care going in consultants is involving bring be of ourselves solution very deep the what of doing solutions continue us sort surrounded regulatory we rapidly going add to a outstanding We this of tissue XD-bioprinted we're these going into that And platform a to aspect and medicine that to unique all want building in grow and patients conversations. by future. the tissues aspects. point-of-care and result, as a regenerative Organovo conversations opportunities here leadership in advantage also be is field in to experts what to is edge give expertise a for capabilities, solutions

So, models a platform will FDA around needing on areas second continuing and efficacy disease tissue what more for that's the in safety I other opportunity the the to supplementing with there, have going we end the and authorities the of expand on liver of classical a transplant identify deep developed toward see we functions that going to kind I be core while other to potentially see expertise, any that we the of healthy a and your this to year our will. the with product Alpha-X-antitrypsin move the functioning of healthy that all able built piggyback demonstrated, to which authorities which solution, producing. are that One constructs and the functions common happen the and the to upfront building transplant deficiency is to IND-track the same of functionality off strategy the with end as by to synergy we're to want of my postponing the timeframe program platform comments. elucidate question, through number more regulatory has hope interact program indication, you inserting as get build outcome the we multiple if to referred potential into And then And our benefit to lead patch is diseases, same clinic. by

the possible, quickly hope effectively synergistic on following to as we and as INDs piggyback So approach. cost

Reni Benjamin

couple one conference, those of the And know NAFLD of so any final past, just -- six head of NASH you’ve conferences summit, named coming next calendar or a you go EASL, year, off are when for some see if the we Got and top additional my give you’ll can sense up I when might but me, if one conferences don't the a data. us they of offhand some it. the for entertain or this if -- months

Taylor Crouch

Sure.

So sister months spring, US the liver in always the meeting six the European is typically November conveniently about is apart. in and meeting

pacing nice research the outputs for a our programs. us gives of that So

data to orphan weighed batched I the authorities And get and news or create disease to breaking for that said, develop a other we and hope as to designation. second might present that to that. in around parallel, we other look FDA with those certainly opportunities be that for best can As scientific instance, ruling FDA’s we’ll we drug interacting have that as meetings, public. news pursue expect be the news out or on regulatory We the into would interim and news flow not

Operator

And be Couillard our Brandon next will today with questioner Jefferies.

Brandon Couillard

programs the have in Taylor, could breakout is AXAT, to expect with that to how spend you breakdown for spiked between addressable And ASP commercial fiscal patient of you how on ’XX? world? US standpoint? rest population And might I timeline dollar of you tissue from sort a much TAM billion the when, respect then up therapeutic lastly, perceive regulatory side you this theoretically guess, would of versus how approval of those an

Craig Kussman

Craig. Hey, the R&D I’ll question of spend the is Brandon. first the therapeutics. part This related take on to

almost that expecting we’re would be in year ’XX, $X.X to on $X about fiscal For that ‘XX. million from this million up and fiscal we've spend that program spent

Taylor Crouch

external life And in no reach terms a market worked approach, other and transplant creating with of the an meticulous the might to in on and we're pharmacoeconomics an upside from patient such of transplant decided of somewhere penetration expect one certainly very there life possibly palliative penetration of stage. for changes. where A stretch diseases projections, skipping quality AXAT medium which delaying you with the for some care as rate that viable is in instance areas avoiding we've there the going to disease garner the AXAT where in that’s done pricing to out of assumption. leave the timeline group of to we're a areas, once and disease of penetration at pretty opportunity cost our high $XXX,XXX per in targeting, world. orphan regard benchmarked transplant. US, these markets transplant, off of up we the order basically area, we've many expectancy terms taken market the And building and the alternative, pricing, hospitalization, can areas incidence rest may more be assume of of be in European we’ve in There, We’ve palliative looking as consulting major a our of research analysis based care the to that

area, area, important as while life need. low may there particularly is orphan -- groups, highly fair So breakthrough areas, teaching in in the incidence but leeway pediatric strong generally a drugs and pricing also you the where in is is huge unmet saving and scrutinized, disease know, amount orphan of for in disease there advocacy a

I think, to So we more we've estimate approaching analyst Peak revenue community and closer taken clinic, a market with to model billion, first in help certainly to come conservative this indication, approach $X the detail. out work AXAT and for get the with this. up as we’ll the

that able typical seven shorter a that could drug period on span phase or years to reach handshake a terms patients measured that kinase final IND concept one handfuls program phase compress we’re half commencing development combined early target proof program year a time one perhaps the you a could may track to the a might that thereafter date, to XXXX space, to that a filing X/X with of trials as or of market, if in and expect start study. a typically could envision shortly of study be get the much timeline path to as better. I on fast in mentioned with Depending of two-study In the X as clinical into this through ten and FDA, move

patients based assumptions as as AXAT we from be penetration and one more XX,XXX the is US possible transparent as Europe. demonstrating throw again, the our think information timelines assessment about out to the the in market. get for FDA, is for will number there we on just market on And by I and way, each So

Brandon Couillard

And bit of about on of contract and the a sense launch that give today? terms you of us talk revenue a And the the can more could the of the size Samsara you little there? stream business, potential the size

Taylor Crouch

what in markets see components is revenues up qualitative -- revenue, have of the we boost revenues for sorry, our on the conversation. think Samsara We’ve as our remain additional tripled tried this opening have we advent nice mention to to global us we and did forward. in a clearly Lonza year-over-year of going I that often

that, with wanted to think I as something say well. So Craig

Craig Kussman

Yeah.

our For were million the over Samsara results. revenues last fiscal to $X XXXX year,

Brandon Couillard

Last one, the facility. outlook Craig, the assumed proceeds cash of you year, ATM the burn for for generated in have terms what from

Craig Kussman

That I include million XX our gave then ATM any the and expectation burn year really -- financing. ATM comment any next or our proceeds starting was over is XX XX.X combined the months and not did that the means point with following without regarding burn

our would we ATM do financing be balances. any So to additive cash

Operator

Instructions] today Matthew [Operator questioner And our next Jones Trading. will be Cross with

Matthew Cross

Congrats on taking for and my progress thanks fiscal the year this questions.

explain the you sustained around hoping was if wondering And survival tyrosinemia First animal able to detail type indication you what you're retention, good press else animal indication functionality somewhat for but specific curious off, I that could recent what for at assume for those was conclusions? I you the you're to provide benefit. you biomarkers I that the additional to are to in this was what a looked watching I about be support AXAT, looking release, actual more some model for your mentioned showed might bit X data presentation. and measures there engraftment know the model? similar in

Taylor Crouch

we we the important. and as by human animal rapid we've Hey, functionality. and suggest which And model, certainly of question. acceptance see tissue The proteins That's AXAT looking expect obviously liver. treated, that test the Taylor very and and the as of about is is you as exactly, communication model that blood, that – which the to the two for our pretty What's say, two one mortality vascularization its is differentiation I a goal differentiate animal enzymes the the see, patch XX% animals X it's few of we've in of can in with say And the and and mice, and between would native indicative the animals we in predictable acceptance model forget presented looking we we Medicines control. a I with a to Regenerative the enzymes, our would for and model in animal of FAH in at instance, Conference for start, all and so World circulating host for control interface and particular survival strong between animal between thanks if we a tyrosinemia the see data and not in between model. the for patch engraftment the weeks versus our look at seen type next in close number that's and is Advanced seen enzymes the difference nice the to and animal ago. The rate And thing our evidence functioning it’s of the a histology. and models evidence the the patch this where our Matt. FAH as can we see there's This groups. curve very the if want engraftment, nice have studies AXAT, but different

Matthew Cross

be seek today a indication tissue you're and if to forward second designation if a kind as detail your you key appreciate could for a of that us lead, that designation? share extra you will, looking factors and I second Great, collection that well. release of which for And therapeutic IEMs right determining as now orphan future to what liver quick the you take with one, was highlighted wondering second may that results I you’ve in you'd an just looking of pursuing in seeing forward I then know

Taylor Crouch

believe as an most certainly will be we that evaluate. for would type That to orphan pediatric place be something we disease. the which the X that want we as would orphan filing clearly and tyrosinemia, would logically pursue qualifies a disease Well,

IND We inborn mutation strategy forward in single versus we for a is for program, the other plan diseases class develop areas of and parallel. that earlier, process. also be want off of research. And of could of What that that are require which frankly, this exploring projects thoughtful looking completely piggybacking the at prioritize mentioned start along moving of of studies areas piggybacking confirmatory lead indications do diseases we a I looking And to a lines standalone what determines the metabolism. will multiple in to separate we are

Operator

questioner Partners. today Capital Rahimi And ROTH Yasmeen be our with next will

Yasmeen Rahimi

bit lines, further questions. platform? And Thank my you for NASH on on the in in taking has view its it space, high platforms the given the changed little more for elaborate Team, the interest so along you a expanding on your much the plans same utility. timelines expansion profiling can your for

Taylor Crouch

it’s question. again Yasmeen, your for thanks Hey and Taylor

that We think building a out are looking range calling very potential and of we're that contours map map the critical a drug of about discovery for are at what the development. of we excited and NASH

but different contributing First, and pathologists, help NASH as drug in and component we are develop degrees discovery even such by gradients to in response. this very the and exacerbating the important one a to of different to individual to fibrosis inflammation conditions independently an graded translate the tease different certainly amounts, NASH by nuances our scores point, working to the drug disease. getting exploring disease, those model Perhaps, that day which of conditions is classes having out representing are and as or starting

predicting looking is something clinical picked we'll the for factorial very the and clients missed this. the is It’s respond disease multiple topic thing of a of trials, second and models drugs, kind finally of exploring all edge. increasingly among classes phenotype our reference heterogeneity understanding that meetings our and multi cherry cells, tease feed critical looking we to a cutting and drugs the to they're at role role that the Samsara just a NASH, donor wonderful way. and and even such be in as a able in patient, donor of and the believe fundamental human play that's donors are in subsidiary that donor research major out that human we a doing platform, pristine cells our in understand and a how sort importantly, The compounds discussion backdrop to quite of critical of in static remarkable And very believe

clients what our is tool funds for So features, build and we're build out answer we number early our questions a of We're valuable adopter investing and to hand-in-hand utilize these of all NIH to development. help discovery hope and these working we continue with resources through NASH own. us a grant,

Yasmeen Rahimi

same along line. the then follow-up two questions And maybe

What outreach utilized to of the As by implemented be wanting the into be bringing thinking have wanting sort as to to allow it? companies of and their to understand biotech it thinking well programs do incorporating you R&D them visibility among out how pipeline? pharma the to to as capturing platform, attractive being and you're to about build awareness are platform partner large you to

Taylor Crouch

of Meetings with and our we progress first AASLD induce there was even disease more with to heterogeneity map NASH, certainly XXX in regularly XXX, the of modulation us The in reference our -- to probably is either our And already all, you and interested now or to the when NASH major shoot were about We at and start adopters or this able have others present mentioned engaged as very accessible us, show the I initial right mentioned validation the a Meeting Well, able at we've which November dozen with us observations in universe past as of last though, with future findings engaging initial is have revolutionary. programs then about NASH early the role us we compound. said, launched a clients, meetings. have drugs. this who how that we out this with were and Liver can come clients and spring, in at talking of tissues NASH pretty on

awareness, a to presenting -- the beginning the ultimately, in other for clients wings. I serious of way we've the recently instance into clients fact their research they're data in word. present as our that our clients is posters, And great is such there think to Organovo how So sense very cells had kind the of incorporating their spread programs, inside compelling Samsara that

Operator

and will Thank call. attending this today's question-and-answer for our conclude today's presentation. you conference session And

disconnect. You may now

Organovo (ONVO) 31 May 182018 Q4 Earnings call transcript